CPR Therapeutics receives first patent for multi modal CPR Technology
FOR IMMEDIATE RELEASE
CPR Therapeutics Inc. announced today that the company has received a U.S. patent for technology that underlies its multi modal cardiopulmonary resuscitation (CPR) system: U.S. 10,772,793 B2 – MECHANICAL CARDIOPULMONARY RESUSCITATION COMBINING CIRCUMFERENTIAL CONSTRICTION AND ANTEROPOSTERIOR COMPRESSION OF THE CHEST.
CPR Therapeutics Inc. is developing the first advanced technology automated CPR system that integrates and synchronizes multiple innovations into a single system that can be easily applied under emergency conditions. This multi modal CPR cannot be performed by humans, and significantly increases blood flow to the heart and brain while enhancing electrical counter-shock in ways previously only available in laboratory settings. Increased blood flow and more effective counter shock both contribute better patient outcomes in cardiac arrest, the leader single killer in Western Countries.
Norman Paradis MD, CPR Therapeutics Founder and CEO stated: “This is an important milestone for the company. We strongly believe that previous automated CPR devices failed their clinical trials because their single-pump CPR was not sufficiently effective. Our multi modal CPR addresses this major limitation by combining thoracic, cardiac and abdominal pump mechanisms. We are obviously pleased that the U.S. Patent Office has issued this foundational patent.”
Dr. Henry Halperin, the Company’s Chief Scientific Officer: “Studies in my laboratory at John’s Hopkins showed that multi modal CPR is dramatically more effective than manual CPR or the other existing CPR devices. It seems increasingly likely that there is important patient-to-patient variability in the underlying CPR pump mechanisms. The CPR Therapeutics’ approach will give each patient maximal forward blood flow and the greatest chance of being successfully resuscitated. The company’s pending patent applications are equally innovative.”
Dr. Paradis further added: “This is a major milestone for the company, and this patent adds to our first-mover advantage with respect to multi modal CPR. It would be hard to underestimate the head-start we have in developing the first widely applicable effective innovation for the treatment of this major unmet medical need.”
CPR Therapeutics Inc.
CPR Therapeutics Inc. is a seed-stage medical device company developing the next generation system for cardiopulmonary resuscitation.
Sudden cardiac arrest may be the largest single cause of death and years of lost life in Western countries. Improving the outcome of patients after cardiac arrest is one of the great unmet medical needs. Each year over 300,000 deaths occur following sudden cardiac arrest in the U.S. alone. Fifty years after the first description of modern cardiopulmonary resuscitation (CPR) survival is below 10%, and the standard-of-care for these patients remains manual chest compressions performed by rescuers with their hands.
CPR Therapeutics Inc. is developing the first advanced technology automated CPR system that integrates and synchronizes multiple technological innovations into a single system that can be easily applied under emergency conditions. This advanced technology multimodal CPR cannot be performed by humans. It will enhance blood flow and the efficacy of electrical countershock in ways previously only available in laboratory settings. This system will, for the first time, demonstrate clinically significant improved survival. Info@CPRTherapeutics.com
DISCLAIMER: The information provided pertaining to CPR Therapeutics Inc. (“CPR-T” or the “Company”), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, CPR-T and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and CPR-T expressly disclaims any and all liability that may be based on such information or errors or omissions thereof. CPR-T reserves the right toamend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amendedinformation or to notify the recipient thereof.